Skip to main content

Table 1 Laboratory variables of control patients and AST-120-treated patients

From: Oral Adsorbent AST-120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure

  Control patients AST-120-treated patients
Baseline After 3 months Before treatment After 3 months of treatment
Body weight (kg) 57.9 ± 11.7 57.2 ± 12.7 58.3 ± 11.1 57.9 ±11.4
Fasting plasma glucose (mg/dL) 85.2 ±6.4 83.8 ± 4.6 90.8 ± 4.0 89.8 ± 4.8
Systolic BP (mmHg) 126 ± 21 136 ± 8.4 123 ± 16 125 ± 29
Diastolic BP (mmHg) 68 ± 8.8 72 ± 11 74 ±9.4 72 ± 9.2
BUN (mg/dL) 44.4 ± 18.5 49.1 ± 20.9 52.3 ± 18.3 49.6 ± 21.7
Serum creatinine (mg/dL) 4.5 ± 2.0 4.9 ± 2.0 4.4 ±1.7 4.8 ± 1.9
Urinary protein excretion (g/day) 2.3 ± 1.7 3.0 ±3.3 1.8 ±1.5 1.5 ± 1.3a
  1. aP < 0.05 compared with the value before AST-120 treatment.